rawfin.tv
Eli Lilly Pancreatic Cancer Drug Gains FDA Orphan Designation
RegulationstocksAI Generated

Eli Lilly Pancreatic Cancer Drug Gains FDA Orphan Designation

By rawfin.tv Markets Desk||Updated |1 min read|AI-assisted · Methodology

Eli Lilly's experimental pancreatic cancer drug, olomorasib, has received orphan drug designation from the FDA, a key regulatory milestone. This designation supports the company's expansion beyond its GLP-1 drug portfolio into oncology.

LLYPharmaceuticalsFDAOncologyDrug Development

Related Articles

EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks
S&P 500 Early Reporters Show 83 Percent Surpass EPS Estimates

S&P 500 Early Reporters Show 83 Percent Surpass EPS Estimates

stocks